Although Alzheimer's disease (AD) is highly heritable, genetic variants known to be associated 22 with AD only explain a small proportion of its heritability. Genetic factors may only convey 23 disease risk in individuals with certain environmental exposures, suggesting that a multi-omics 24 approach could reveal underlying mechanisms contributing to complex traits, such as AD. We 25 developed an integrated network to investigate relationships between metabolomics, genomics, 26 and AD risk factors using Wisconsin Registry for Alzheimer's Prevention participants. Analyses 27 included 1,111 non-Hispanic Caucasian participants with whole blood expression for 11,376 28 genes (imputed from dense genome-wide genotyping), 1,097 fasting plasma metabolites, and 17 29 AD risk factors. A subset of 155 individuals also had 364 fasting cerebral spinal fluid (CSF) 30 metabolites. After adjusting each of these 12,854 variables for potential confounders, we 31 developed an undirected graphical network, representing all significant pairwise correlations 32 upon adjusting for multiple testing. There were many instances of genes being indirectly linked 33 to AD risk factors through metabolites, suggesting that genes may influence AD risk through 34 particular metabolites. Follow-up analyses suggested that glycine mediates the relationship 35 between CPS1 and measures of cardiovascular and diabetes risk, including body mass index, 36 waist-hip ratio, inflammation, and insulin resistance. Further, 38 CSF metabolites explained 37 more than 60% of the variance of CSF levels of tau, a detrimental protein that accumulates in the 38 brain of AD patients and is necessary for its diagnosis. These results further our understanding of 39 underlying mechanisms contributing to AD risk while demonstrating the utility of generating and 40 integrating multiple omics data types. Alzheimer's disease (AD) is an example of such a trait: 53% of its phenotypic variance can be 48 explained by genomic variants, collectively (i.e., SNP heritability); yet, the 21 GWAS variants 49 identified in a meta-analysis to be associated with AD only account for 31% of its genetic 50 variance, leaving 69% unaccounted for(2). In order to more comprehensively understand the 51 disease risk conveyed by genetic factors, it is crucial to consider genomics in combination with 52 other omics data types and to use integrative multi-omics approaches that can capture intricate 53
Introduction 44
Genome-wide association studies (GWAS) have identified tens of thousands of single 45 nucleotide polymorphism (SNP)-trait associations(1). However, these variants tend to have very 46 small effect sizes and typically explain a small portion of trait heritability. Late onset 47
Alzheimer's disease (AD) is an example of such a trait: 53% of its phenotypic variance can be 48 explained by genomic variants, collectively (i.e., SNP heritability); yet, the 21 GWAS variants 49 identified in a meta-analysis to be associated with AD only account for 31% of its genetic 50 variance, leaving 69% unaccounted for(2). In order to more comprehensively understand the 51 disease risk conveyed by genetic factors, it is crucial to consider genomics in combination with 52 other omics data types and to use integrative multi-omics approaches that can capture intricate 53
relationships. 54
Although there has been great interest recently in the integration of multi-omics datasets, 55 progress in this field is still fairly limited and it faces many challenges(3-8). However, studies 56 have been able to show that the use of multiple omics data types is more predictive than single 57 data types (5, 9) . A recent study with dense longitudinal omics data displayed the utility of 58 integrating such data with regards to personalized medicine(10). Although limited by its sample 59 size of 108 participants, this investigation identified meaningful systems biology relationships 60 that were able to improve the health of its participants. As it is becoming more feasible and 61 common to acquire multiple omics data types, it is essential that we move towards systems 62 biology approaches of understanding complex diseases, rather than focusing on single data types 63 that are unable to capture the intricacies imposed by biology. 64 sequencing on whole blood and GWAS data. PrediXcan filters results to only include genes that 203 are imputed with reasonable accuracy, using a false discovery rate of 0.05. After removing genes 204 with zero variability between individuals (162 genes), whole blood gene expression data for 205 11,376 genes were available for analyses. 206
Integrative network analysis 207
The analytic approach we used for our network analysis was similar to that of Price et al., 208 2017(10) . A total of 12,856 variables, including 11,376 expressed genes, 1,097 plasma 209 metabolites, 364 CSF metabolites, and 17 AD risk factors, were available for the network 210 analysis. Linear mixed models, as implemented by the lme4 package in R(36), were used to 211 adjust each variable for age and sex and included a random intercept for individual to account for 212 repeated measures and family to account for sibling relationships. Further adjustments were 213 made specific to the variable being assessed: imputed gene expression was also adjusted for the 214 first four principal components to account for ancestry; CSF and plasma metabolites were 215 adjusted for cholesterol lowering medication use and sample storage time; the executive function 216 and delayed recall composite scores were adjusted for practice effects; and systolic and diastolic 217 blood pressure were adjusted for ace inhibitor and beta blocker medication use. For longitudinal 218 traits (such as metabolites), random intercepts were used as the new outcomes for each 219 individual, whereas for constant traits (such as imputed gene expression values), residuals were 220 used as the new outcomes for each individual. These adjusted outcomes were used to assess all 221 82,606,231 pairwise correlations between traits using Spearman rank, and significance was 222 determined using a 606, . To identify 223 relationships between omics data, significant inter-omic associations and significant associations 224 with an AD risk factor were used to develop an integrative network, which was created using the 225 igraph R package(37). Dense subgraphs were identified using a community detection algorithm 226 that maximizes the modularity of the network, such that there is high connectivity within 227 communities (or groups of distinct variables), but low connectivity between communities(38). 228
Targeted mediation and interaction analyses 229
Results from the integrated network analysis were used to identify potential mediation 230 and interactions between imputed gene expression and metabolite levels that could impact AD 231 risk factors, as a proof of concept. Although our network analysis suggested many potentially 232 meaningful mediation or interaction relationships, we only investigated gene-metabolite 233 correlations with the most consistent biological support from the GWAS catalog (1) 234 (www.ebi.ac.uk/gwas, date accessed: May 9, 2018), to illustrate the utility of the network 235 analysis results. Such relationships were investigated using the longitudinal data (2,198 236 observations among 1,111 individuals) with linear mixed models, again as implemented by the 237 lme4 package in R(36), including random intercepts for within-individual repeated measures and 238 within-family relationships. To assess whether a metabolite mediated the relationship between 239 imputed gene expression and an AD risk factor, models were run to assess whether: 1) the gene 240 predicted the AD risk factor, 2) the gene predicted metabolite levels, 3) the metabolite predicted 241 the AD risk factor, and 4) the gene predicted the AD risk factor while adjusting for the 242 metabolite. The causal mediation effect, or the indirect effect of a gene on an AD risk factor 243 through a metabolite, was calculated as the difference between the effect of the gene in model 1 244 and model 4, as implemented in the R mediation package(39). To determine whether this 245 difference was significant, standard errors and P-values were estimated using the quasi-Bayesian 246
Monte Carlo method with 1,000 simulations. Because the mediation package can only handle 247 mixed models with one random effect, the mediation analysis was run with models 1 and 4 248 excluding the random effect for family. As a sensitivity analysis, the mediation analysis was 249 rerun limiting models 1 and 4 to unrelated individuals (n=898 with 1,774 observations pathway, and sub pathway are described in Table S1 , and numbers of metabolites within each 268 super pathway are summarized in Table S2 . 269
Correlation between plasma and CSF metabolomics 270
13
The median correlation between the 326 metabolites common to both plasma and CSF 271 was r=0.26, with some variability existing between different metabolite pathways (Figure 1) . 272
Xenobiotics had the highest median correlation (r=0.53), while lipids had the lowest (r=0.11). 273
Overall, metabolite correlations ranged from |r|=0.0002 (inosine, a nucleotide) to |r|=0.88 274 (quinate, a xenobiotic). Interestingly, one of the highest correlations was caffeine (r=0.81). 275
Correlations between each of the 326 CSF and plasma metabolites are described in Table S3 . 276
Integrated network 277
After applying a Bonferroni correction for multiple testing, a total of 90,308 significant 278 correlations (edges) among 10,869 variables (nodes) were used to develop an overall 'hairball' 279 network ( Figure S2 ). Notably, although there were far fewer metabolites than genes in the 280 network (1,387 metabolites versus 9,481 genes), there were more edges between metabolites 281 than genes (49,499 versus 37,473 edges, respectively). 282
The inter-omic network is shown in Figure 2 (a labeled version is shown in Figure S3 ), 283 and its corresponding community partitions are shown in Figure S4 . This network had 1,224 284 edges and 635 nodes, including 171 metabolite-gene and 833 metabolite-AD risk factor edges. 285
Of these, there were only four CSF metabolite-gene edges and 73 CSF metabolite-AD risk factor 286 edges, likely due to the much smaller number of CSF metabolomic samples. No genes were 287 directly linked to AD risk factors; however, many genes were indirectly linked to AD risk factors 288 through metabolites, as described below. Each of the 1,224 correlations is described in Table S4 . 289
The largest community contained 680 edges among 289 nodes, which included 264 290 plasma metabolites, ten CSF metabolites, eight genes, and seven AD risk factors related to 291 cardiovascular disease and diabetes: body mass index (BMI), waist-hip ratio (WHR), 292 homeostatic model assessment of insulin resistance (HOMA-IR), interleukin 6 (IL-6), metabolic 293 14 equivalents (METs), diastolic blood pressure (DBP), and systolic blood pressure (SBP) (Figure  294 S5). Expression levels of these eight genes were all indirectly linked to AD risk factors within 295 this community through plasma metabolites. CPS1 expression levels were negatively correlated 296 with plasma gamma-glutamylglycine, proprionylglycine, and glycine levels, all of which were 297 negatively correlated with BMI, WHR, IL-6, and/or HOMA-IR (Figure 3 ). TMEM229B and 298 PLEKHH1 were both negatively correlated with two glycerophosphatidylcholines (1-(1-enyl-299 palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) and 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-300 16:0/16:0)), which were also negatively correlated with BMI, WHR, and/or HOMA-IR. 301 NAALAD2 was negatively correlated with an amino acid beta-citrylglutamate, which was 302 positively correlated with BMI, WHR, IL-6, and HOMA-IR. ZNF655 and ZKSCAN1 were both 303 positively correlated with X-12063, which was also positively correlated with BMI, WHR, and 304 HOMA-IR. CHRNA5 was positively correlated with 5-hydroxylysine, which was positively 305 correlated with BMI, WHR, IL-6, and HOMA-IR, and negatively correlated with METs. ARVCF 306 was negatively correlated with X-11593, which was positively correlated with BMI, IL-6, and 307
HOMA-IR. 308
Several genes outside of the cardiovascular and diabetes community were indirectly 309 linked to AD risk factors within this community. Gene expression of FOSL2, KRTCAP3, and 310 ZNF513 were positively correlated, while IFT172, NRBP1, PPM1G, and ZNF512 were 311 negatively correlated, with levels of plasma mannose, a carbohydrate that was positively 312 correlated with BMI, WHR, IL-6, and HOMA-IR ( Figure S6A ). CABP1, SPPL3, and UNC119B 313 expression levels were negatively correlated with plasma butyrylcarnitine (C4), which was 314 positively correlated with BMI, WHR, IL-6, and HOMA-IR ( Figure S6B ). SLC27A4, PHYHD1, 315 ENDOG, and SH3GLB2 expression levels were negatively correlated with plasma 2'-O-316 methyluridine and 2'-O-methylcytidine levels, both nucleotides involved in pyrimidine 317 metabolism, and the latter nucleotide is also negatively correlated with BMI and WHR ( Figure  318 S6C). PHYHD1 was also negatively correlated with CSF levels of 2'-O-methylcytidine. 319
The only correlations identified among the CSF biomarkers (i.e., amyloid and tau) are 320 shown in Figure 4 . Higher CSF T-tau and P-tau levels were correlated with higher levels of 38 321 CSF metabolites, collectively. These metabolites included 13 lipids (six phosphatidylcholines, 322 two lysophosphatidylcholines, five sphingolipids, and cholesterol), seven amino acids, five 323 carbohydrates, one nucleotide, one energy metabolite, one cofactor and vitamin metabolite, one 324 xenobiotic, and nine unknown metabolites. However, none of the CSF amyloid biomarkers were 325 correlated with CSF metabolites. We investigated how much of the variance of T-tau and P-tau 326 could be explained by these metabolites with linear mixed models that included random 327 intercepts for within-subject repeated measures and within-family relationships, using the R 2 328 statistic for mixed models as defined by Edwards et al., 2008(40) and implemented in the 329 r2glmm R package. After removing the variation explained by age and sex, the 37 metabolites 330 correlated with T-tau explained 60.7% of the variation of T-tau, while the 35 metabolites 331 correlated with P-tau explained 64.0% of the variation of P-tau. 332
Targeted mediation and interaction analyses 333
Targeted mediation and interaction analyses were focused on a particular pathway 334 identified within the large cardiovascular and diabetes community involving CPS1, glycine 335 plasma metabolites (glycine, proprionylglycine, and gamma-glutamylglycine), BMI, WHR, IL-6, 336
and HOMA-IR. Associations between CPS1 variants and glycine have been reported in at least 337 nine studies (15, 16, (41) (42) (43) (44) (45) (46) (47) , more than any of the other gene-metabolite associations identified in 338 our network analysis, and these studies were based not only on Caucasian populations, but also 339 16 on Japanese and African American populations. Many previous studies have also reported 340 associations between glycine and cardiovascular risk factors, including BMI, waist 341 circumference, inflammation, and HOMA-IR (45, (48) (49) (50) (51) (52) (53) (54) (55) . This evidence made this pathway a 342 strong candidate for mediation and interaction analyses. 343 Figure 5 shows results from the mediation analyses using glycine as the mediator, 344 including the total effect (i.e., the effect of CPS1 in the model unadjusted for glycine), the direct 345 effect (i.e., the effect of CPS1 in the model adjusted for glycine), and the indirect effect (i.e., the 346 effect of CPS1 due to the effect of CPS1 on glycine) for BMI (Figure 5A and Figure5B) , WHR 347 ( Figure 5C and Figure 5D ), IL-6 ( Figure 5E and Figure 5F ), and HOMA-IR ( Figure 5G and 348 Figure 5H ). The total effect of CPS1 was null for each of these three outcomes, likely due to the 349 negative association between CPS1 and glycine coupled with the negative association between 350 glycine and the AD risk factor, resulting in direct and indirect effects that had opposing 351 directions(56). Our results show that lower levels of CPS1 expression lead to increased glycine 352 levels, and higher glycine levels lead to decreased BMI, WHR, IL-6, and HOMA-IR. Thus, with 353 glycine as a mediator, lower levels of CPS1 lead to decreased BMI, WHR, IL-6, and HOMA-IR. 354
Mediation analyses using propionylglycine and gamma-glutamylglycine as the mediator showed 355 similar results and can be found in Figure S7 and Figure S8 . We did not identify any interactions 356 between CPS1 and the three glycine metabolites that were associated with BMI, WHR, IL-6, or 357
HOMA-IR (all P-values>0.07). 358 359 Discussion 360
We developed an integrative network to investigate relationships between genomics, 361 plasma metabolomics, CSF metabolomics, and AD risk factors. Although no gene expression 362 levels were directly correlated with AD risk factors, there were many instances of genes being 363 indirectly correlated with AD risk factors though metabolites. Building on one such instance, we 364 found that glycine mediated the pathway between CPS1 expression and cardiovascular and 365 diabetes risk factors. This suggests that our results may have generated many valid hypotheses 366 that warrant further investigation. We also found that correlations between plasma and CSF 367 metabolites ranged widely but typically had low correlations. This could suggest that most 368 plasma metabolites are not representative of certain metabolic changes occurring in the brain, 369 although we cannot rule out the possibility that the low average correlation is, at least partially, 370 due to the time difference between the plasma and CSF sample collection. 371
The low correlation we observed between plasma and CSF metabolite levels could be 372 related to ~98% of small molecules not being able to pass the blood-brain barrier (BBB)(57). 373
Cholesterol is an example of a lipid metabolite that typically cannot pass the BBB(58), and was 374 not correlated between tissues (r=-0.07). On the other hand, caffeine (a xenobiotic) readily 375 crosses the BBB(59) and it was highly correlated between tissues (r=0.81), as was 5-376 acetylamino-6-amino-3-methyluracil (r=0.82), which is a caffeine metabolite, and theophylline 377 (r=0.82), which is structurally and pharmacologically similar to caffeine. This could contribute to 378 lipids having the weakest average correlation and xenobiotics having the strongest average 379 correlation between plasma and CSF tissues. However, it is important to note that metabolites 380 within a given pathway can vary widely from each other and should be considered on an 381 individual basis, accordingly, as the averages presented here may not reflect a particular 382 metabolite's unique properties. The hypothesis about plasma and CSF differing due to the BBB 383 is also supported by the only correlations in the network analysis involving CSF biomarkers (i.e., 384 tau) being with CSF metabolites, although we cannot rule out the possibility that this correlation 385 is related to CSF biomarkers and CSF metabolomics being analyzed from the same sample and 386 thus, not having time-related variation. 387
Our network analysis revealed that 38 CSF metabolites were highly predictive of CSF T-388 tau and P-tau, collectively explaining 60.7% and 64.0% of the variance of T-tau and P-tau, 389
respectively. Further investigations of these CSF metabolites could lead to a better understanding 390 of mechanisms and pathways that influence the development of tau tangles. In contrast, no CSF 391 metabolites were correlated with CSF amyloid biomarkers, which could have implications about 392 the biological function of amyloid versus tau. It is possible that we did not capture the small 393 molecules that amyloid may be associated with, or that amyloid is generally not associated with 394 small molecules. Although our CSF findings were limited by their small sample size, they offer 395 potentially novel information regarding the interface between CSF biomarkers and CSF 396 metabolites, as we have not identified previous studies investigating these relationships. 397
One advantage of using imputed gene expression data is that it only represents the 398 genetically regulated component of gene expression, reducing the risk of confounding due to 399 environmental factors and reverse causality in mediation analyses. We found that glycine 400 mediated the relationship between CPS1 and BMI, WHR, IL-6, and HOMA-IR, such that lower 401 CPS1 expression was associated with higher levels of glycine, which were associated with lower 402 BMI, WHR, IL-6, and HOMA-IR. Relationships between CPS1, glycine, and cardiovascular risk 403 associations with betaine, a derivative of glycine (15, 16, 82) . Glycine is a common amino acid 416 involved in the production of DNA, phospholipids, and collagen, and in the release of energy. 417
Previous studies have identified negative correlations between glycine and cardiovascular and 418 diabetes risk factors such as BMI, waist circumference, HOMA-IR, obesity and visceral obesity, 419 subcutaneous and visceral fat area, hypertension, and acute myocardial infarction (45, (48) (49) (50) (51) (52) (53) (54) (55) . 420
These previous findings are in the same direction as our findings and are highly supportive of the 421 biological relevance of our results, which lead us to hypothesize that the CPS1-cardiovascular 422 risk pathway is linked through the mediation of glycine. 423
One particular CPS1 variant, rs715, has been linked to urine and blood glycine levels (15, 424 16, 43-45) , blood levels of betaine (15, 16, 82) , blood levels of fibrinogen (66, 67), and BMI(80) . 425 This is a common variant, with a MAF=0.27 based on 62,784 whole genome sequences from 426
Trans-Omics for Precision Medicine (TOPMed)(83). The minor C allele of rs715 decreases 427
CPS1 expression(82). To further test our findings, we conducted additional mediation analyses 428 using this variant and found highly consistent results, suggesting that having one or two minor 429 alleles of rs715 (which decreases CPS1 expression) increases levels of the three glycine plasma 430 20 metabolites, which decreases BMI, WHR, IL-6, and HOMA-IR (Figures S9-S11) . Thus, the 431 minor C allele of rs715 may have a protective role in cardiovascular risk. 432
One of the primary strengths of this analysis is that it shows the feasibility of performing 433 integrated omics analyses and the potential utility of such approaches. It is becoming more 434 common for cohorts to collect such datasets; for example, the National Institutes of Health is 435 sponsoring the new TOPMed nation-wide consortium that aims to deeply phenotype its 436 participants utilizing omics technologies (www.nhlbiwgs.org). It is anticipated that initiatives 437 such as TOPMed will greatly advance our knowledge of many complex diseases and traits. 438
However, to fully utilize these rich data, it will be crucial to identify effective means of 439 integrating them and maximize their potential to provide a more holistic understanding of the 440 disease process. While there is still a great need for such methods, our inter-omic network 441 analysis and subsequent targeted follow-up analyses outlines one approach to effectively 442 integrate omics data. 443
This study was not without limitations. Due to computational burdens, our network 444 analysis did not fully utilize the longitudinal aspect of our data. Further, our sample sizes for 445 CSF biomarkers and metabolites were limited, which is likely why we had few CSF findings in 446 our network analysis. Plasma and CSF samples typically were not collected on the same day, 447 which could influence our correlation results. However, this may not have influenced our 448 network analysis to a large extent because we averaged the residuals of longitudinal traits. We 449 were unable to include smoking behavior in our network analysis due to the prohibitive number 450 of smokers in our cohort (n=48). Despite these limitations, we were encouraged to find that 451 many of our results had been previously reported, thereby strengthening confidence in our novel 452
findings. 453 21
Opponents of the "big data" era have criticized omics approaches because they are not 454 hypothesis driven and do not follow the standard scientific method(84, 85). However, we know 455 biology to be complex far beyond our current understanding. To believe that we currently have 456 the ability to generate valid biological hypotheses to understand complex conditions without data 457 would be a fallacy. This was a lesson learned in the years preceding the completion of the human 458 genome sequence in 2001 when research efforts were heavily invested into targeted genetic loci 459 and genome-wide linkage screens of ~500 loci (86) . This approach was successful for genes that 460 follow Mendelian patterns, such as highly penetrant variants in the BRCA1 and BRCA2 genes 461 that are responsible for inherited forms of breast cancer and the APP, PSEN1, and PSEN2 genes 462 that cause the inherited early onset form of AD. However, it had limited success for traits that 463 follow complex inheritance patterns (86) . The utility of omics data, and particularly integrated 464 omics approaches, is the ability to generate data driven hypotheses. Our knowledge of biology 465 has been evolving for centuries; however, with the data we are able to generate due to recent 466 biotechnological advances, we now have the opportunity to advance our knowledge of biology at 467 an unprecedented rate. Such data could lead to dramatic improvements in the state of 468 preventative and therapeutic medicine, particularly for complex diseases such as AD, for which 469 few such preventative or therapeutic methods exist and little is known about the underlying 470 biological mechanisms. 471
By integrating genomics, metabolomics, and clinical risk factors for AD, we were able to 472 identify complex relationships that offer insight into the onset of AD and risk factors associated 473 with its onset. Our research has generated many promising hypotheses that could drive 474 subsequent experimental investigations and potentially offer clinicians and researchers new 475 insights regarding the development of tau tangles. As the generation of omics data accelerates 476 22 across investigations of a variety of research fields, continued efforts to navigate statistical and 477 computational issues will be critical. The work presented here represents early efforts to integrate 478 omics data, but much more research is needed to identify the most effective means of doing so 479 and thereby maximize the utility of such rich sources of data. The success of precision medicine 480 is heavily reliant on the advancement of computational biology and the ability to translate 481 millions of biological data points into individual clinical implications. 
